Status:
COMPLETED
BacterioPHAGE for Gastrointestinal Health 2 Study
Lead Sponsor:
Colorado State University
Conditions:
Mild Gastrointestinal Symptoms in Healthy Adults
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The BacterioPHAGE for Gastrointestinal Health-2 study is designed to determine if a commercial bacteriophage product can increase the survival and efficacy of probiotic bacteria that will be concurren...
Detailed Description
The commercial bacteriophage preparation,PreforPro, is often found as an ingredient in commercial probiotcs, so the goal of the current study is to determine if PreforPro consumption concurrent with p...
Eligibility Criteria
Inclusion
- healthy
- 18-65 years old
- BMI 20 to 34.9
Exclusion
- individuals less than 18 years of age or greater than 65 years of age
- outside of the BMI range of 20-34.9
- antibiotic or probiotic/prebiotic supplements within two months of the start of treatment
- use of statins, metformin, NSAIDs, MAO inhibitors, and botanical supplements that target the GI tract or gut microbiota
- current diagnosis of cancer, liver or kidney disease, gastrointestinal diseases, and metabolic disorders
- pregnant and breastfeeding women
- unable to adhere to the study requirements
Key Trial Info
Start Date :
October 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2020
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT04511221
Start Date
October 1 2018
End Date
March 31 2020
Last Update
August 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Colorado State University
Fort Collins, Colorado, United States, 80523-1571